All In Biotech

Drug Trial Radar · NCT07502534

A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

A Phase I, Randomized, Double-masked, Parallel-group Clinical Trial Evaluating the Bioequivalence and Safety of a Single Subcutaneous Dose of IBI3027 Monoclonal Antibody Injection Versus DUPIXENT® (Dupilumab) in Healthy Adult Chinese Male Volunteers.

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Actual

Start

Apr 24, 2026

Primary completion

Jul 7, 2026

Study completion Jul 7, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-masked, parallel-group, reference-drug-controlled clinical trial of IBI3027 in healthy male volunteers. Healthy volunteers will be randomly assigned in a 1:1 ratio to receive either IBI3027 or DUPIXENT?. The dosage for both groups is 300 mg. The entire study includes a 28-day screening period and a 56-day observation period (including 3 days of hospitalization). Randomization is stratified by body weight at baseline (D1) ≤ 70 kg vs. \> 70 kg.

Conditions

  • Healthy Volunteers

Interventions

  • IBI3027Drug

    The participants in IBI3027 treatment group will receive a 300 mg subcutaneous injection of IBI3027 on the first day.

  • DUPIXENT® (dupilumab)Drug

    The participants in DUPIXENT® (dupilumab) treatment group will receive a 300 mg subcutaneous injection of DUPIXENT® (Dupilumab Injection) on the first day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak drug concentration (Cmax)Time frame: Days 1-57
  2. Area under the plasma concentration-time curve (AUC0-∞).Time frame: Days 1-57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qingdao University Affiliated Hospital

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.